Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's Leqembi (lecanemab-irmb) for maintenance dosing once every four weeks for ...

Q3 2024 Management View CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment. Eisai Co., Ltd. and Biogen Inc. announced that the U.S. FDA ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment Leqembi (lecanemab-irmb) after the US Food and Drug Administration ...

Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...

Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.

Jan 31 (Reuters) - The European medicines regulator said on Friday it will review safety information for Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, nearly three ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2024 (third quarter ...

Eisai reported strong Q3 2024 performance driven by its leading products, particularly LEQEMBI, which saw robust sales growth across key regions. Management expressed confidence in achieving its ...